论文部分内容阅读
作者对１３１Ｉ标记铁蛋白多克隆抗体（１３１Ｉ－ＦｔＡｂ）、抗人肝癌单克隆抗体（１３１Ｉ－Ｈｅｐａｍａ－１ＭｃＡｂ）和乙型肝炎病毒Ｘ蛋白单克隆抗体（１３１Ｉ－ＨＢｘＭｃＡｂ）的药代动力学进行研究。结果：（１）裸鼠人肝癌模型，１３１Ｉ－ＦｔＡｂ分别经静脉（ｉＶ）、腹腔（ｉｐ）途径给药，其药代动力学模式有很大差异，相同剂量的ＦｔＡｂ与ＨＢｘＭｃＡｂ经ｉｐ给药，ｔｍａｘ分别为８．１ｈ和８．４ｈ，Ｔ１／２分别为４０．５ｈ和４３．２ｈ；不同剂量Ｔ的１３１Ｉ－ＨＢｘＭｃＡｂ，低剂量组与高剂量组ｔｍａｘ分别为１４．２ｈ和８．４ｈ，Ｔ１／２分别为３６．１ｈ和４０．５ｈ，两者有差异；（２）肝细胞癌病人：分别经动脉（ｉａ）、ｉｐ给药后的１３１Ｉ－ＦｔＡｂ的药代动力学均为二室模型，Ｔ１／２α分别为９．３ｈ和１１．６ｈ，Ｔ１／２β分别为５６．７ｈ和５４．１ｈ；相同剂量的１３１Ｉ－ＦｔＡｂ与１３１Ｉ－Ｈｅｐａｍａ－１ＭｃＡｂ经ｉａ注射后其药代动力学模型均为二室，Ｔ１／２α分别为９．３ｈ和５．０ｈ，Ｔ１／２β分别为５６．７ｈ和４０．６ｈ提示：１３１Ｉ－ＦｔＡｂ具有与１３１Ｉ－Ｈｅｐａｍａ－１ＭｃＡｂ相似或较优的动力学特征，ＦｔＡｂ仍不失?
The authors studied the pharmacokinetics of 131I-labeled ferritin polyclonal antibody (131I-FtAb), anti-human hepatocellular carcinoma monoclonal antibody (131I-Hepama-1McAb) and hepatitis B virus X monoclonal antibody (131I-HBxMcAb) . Results: (1) The model of human hepatocellular carcinoma in nude mice, 131I-FtAb administered intravenously (iV), intraperitoneal (ip) route, the pharmacokinetic model is very different, the same dose of FtAb and HBxMcAb by ip administration , Tmax were 8.1h and 8.4h respectively, T1 / 2 were 40.5h and 43.2h, respectively; the tmax of 131I-HBxMcAb at different doses were 14.2h and 8.4h , T1 / 2 were 36.1h and 40.5h, both of which were different; (2) Patients with hepatocellular carcinoma: The pharmacokinetics of 131I-FtAb after ia and ip administration were both Room model, T1 / 2α were 9.3h and 11.6h, T1 / 2β were 56.7h and 54.1h; the same dose of 131I-FtAb and 131I-Hepama-1McAb after injection of ia pharmacokinetics Models are two rooms, T1 / 2α respectively .3h and 5.0h, T1 / 2β were 56.7h 40.6h and tips: 131I-FtAb having similar or superior kinetics and 131I-Hepama-1McAb, FtAb still lose?